EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Novel Chemotype LRRK2 Inhibitors Through AlphaFold2-Generated Structure-Based Docking Screen

Rishiram Baral iD, Jeong In Lee, Jun-Goo Jee

International Journal of Molecular Sciences · 09.04.2026 · 27 (8) · 3391

DOI: 10.3390/ijms27083391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.04.2026. Verfasst von Rishiram Baral und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Molecular Docking Simulation, Protein Kinase Inhibitors, Drug Discovery. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Ministry of Oceans and Fisheries, Korea Basic Science Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The structures predicted by AlphaFold can provide unprecedented opportunities for docking screens; however, experimentally validated examples of using the apo-form are limited. This study reports novel chemotype inhibitors targeting the leucine-rich repeat kinase 2 (LRRK2) kinase domain through a docking screen using one of the ensemble structures starting from the template deposited by AlphaFold2. The MODELLER software generated the ensemble. The conformer that showed the best early enrichment of true positives with the mixture of known ligands and their property-matched decoys was selected. The docking screen against approximately 1.3 million small molecules and enzyme-based assays with the LRRK2 kinase domain followed. We selected 17 molecules, excluding those similar to all known kinase inhibitors. Combined with analogs-by-catalog, ten new small molecules with Ki values below 15 μM were discovered, including one sub-μM inhibitor. To test selectivity, enzyme assays with a mutant and six additional kinases, including known off-targets of existing LRRK2 inhibitors, were performed using three inhibitors. The data suggest that the novelty in chemical structure may be insufficient for providing selectivity. Our approach is generally applicable to cases where information on known binders is available but experimental structure is not.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Molecular Docking SimulationProtein Kinase InhibitorsDrug DiscoveryHumansLigandsProtein BindingStructure-Activity Relationship

Stichwörter der Autor:innen

AlphaFold2LRRK2docking screeninhibitorkinase

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Protein Kinase InhibitorsLRRK2 protein, humanLigands

Autor:innen und Institutionen

  • Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.

ORCID-Profile: Rishiram Baral

Förderung

  • Ministry of Education
  • Ministry of Oceans and Fisheries
  • Korea Basic Science Institute

Zitieren

APA

Baral, R., Lee, J. I., & Jee, J. G. (2026). Discovery of Novel Chemotype LRRK2 Inhibitors Through AlphaFold2-Generated Structure-Based Docking Screen. International Journal of Molecular Sciences, 27(8), 3391. https://doi.org/10.3390/ijms27083391

Vancouver

Baral R, Lee JI, Jee JG. Discovery of Novel Chemotype LRRK2 Inhibitors Through AlphaFold2-Generated Structure-Based Docking Screen. International Journal of Molecular Sciences. 2026;27(8):3391. doi:10.3390/ijms27083391

BibTeX
@article{Baral2026,
  author = {Baral, Rishiram and Lee, Jeong In and Jee, Jun-Goo},
  title = {Discovery of Novel Chemotype LRRK2 Inhibitors Through AlphaFold2-Generated Structure-Based Docking Screen},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {8},
  pages = {3391},
  doi = {10.3390/ijms27083391}
}
Kostenlos starten →